Nikkei Science shares CKM syndrome story May 20

On May 20, Nikkei Science’s X account posted a link to a story on cardiovascular-kidney-metabolic, or CKM, syndrome, describing it as a condition that ties heart disease, kidney disease and diabetes together through fat-cell dysfunction. The post referred readers to the July 2026 issue of Nikkei Science, according to the social post cited in science feeds on Wednesday. The framing matches a broader medical concept that has gained traction since the American Heart Association defined CKM syndrome in 2023. The AHA describes CKM syndrome as a systemic disorder connecting heart disease, kidney disease, diabetes and obesity. ### Why is Nikkei Science focusing on fat cells in a story about three organs? The American Heart Association’s 2023 scientific statement says CKM syndrome reflects a “multi-directional relationship” among excess and dysfunctional adiposity, metabolic risk factors, chronic kidney disease and the cardiovascular system. In that framework, adipose tissue is not treated as passive fat storage. It is part of the disease process linking metabolic dysfunction to injury in the heart, kidneys and blood vessels. (professional.heart.org) The AHA’s advisory also defines CKM syndrome as a disorder with connections among heart disease, kidney disease, diabetes and obesity. That makes fat-cell dysfunction central to the syndrome’s logic, even when the visible clinical problems appear in different organs. ### What exactly is CKM syndrome? In October 2023, the American Heart Association published a presidential advisory and companion scientific statement laying out CKM syndrome as a unified framework rather than a single stand-alone diagnosis. (professional.heart.org) The advisory says the syndrome spans metabolic risk factors, chronic kidney disease and cardiovascular disease, and it proposes staging, screening and treatment approaches across that continuum. (professional.heart.org) The National Kidney Foundation says CKM syndrome links heart disease, kidney disease, diabetes, obesity and steatotic liver disease, and says it is “not a disease by itself” but a way to describe how those problems connect. That distinction helps explain why science coverage often focuses on mechanisms — such as inflammation, adiposity and metabolic injury — instead of a single test result. (ahajournals.org) ### How do researchers say the organs are connected? The AHA scientific statement says CKM syndrome produces excess illness and death beyond the sum of its parts, and says metabolic risk factors can cause end-organ damage in the heart, kidneys and vasculature through hemodynamic, metabolic, inflammatory and fibrotic mechanisms. The document also identifies gaps in understanding, including disease mechanisms and why patients with similar weight categories can have different outcomes. (kidney.org) A 2026 review in Nature Reviews Nephrology described CKM syndrome as integrating metabolic dysfunction, chronic kidney disease and cardiovascular disease into one framework. A 2026 review in Biomedicines said the model centers on dysfunctional adiposity and a multiorgan continuum. Those reviews support the same broad idea highlighted in Nikkei Science’s post: adipose dysfunction is being treated as a shared driver, not a side issue. (professional.heart.org) ### Is this mainly a research concept or something doctors already use? The American Heart Association’s advisory says CKM syndrome is meant to guide screening, prevention and management, including interdisciplinary care and attention to social determinants of health. The statement also says there are still major evidence gaps, including early-life screening, lifestyle support, and optimal use of therapies in patients with overlapping cardiovascular, kidney and metabolic risk. (nature.com) JAMA’s 2023 coverage of the advisory said the framework was designed to support a new way of thinking about cardiovascular risk in people who also have kidney disease, obesity or type 2 diabetes. That puts the concept in a transition phase: it is already part of major society guidance, but many details of measurement and treatment are still being refined. ### What should readers watch next? (professional.heart.org) The July 2026 issue of Nikkei Science is the next named publication tied to the May 20 post. The underlying clinical framework remains the American Heart Association’s 2023 CKM advisory and scientific statement in Circulation, which continue to anchor newer reviews and disease-specific studies published in 2026. (ahajournals.org) (jamanetwork.com)